8:16 AM ET
8-K
Investor Presentation
Septerna Investor Presentation
Septerna announced the selection of SEP-204 as a development candidate for Graves’ disease and thyroid eye disease, supported by preclinical data presented at the 2026 American Thyroid Association Annual Meeting. The company also filed an updated corporate presentation for use in meetings with investors and analysts.